Literature DB >> 21170055

Characterization of the proteome, diseases and evolution of the human postsynaptic density.

Alex Bayés1, Louie N van de Lagemaat, Mark O Collins, Mike D R Croning, Ian R Whittle, Jyoti S Choudhary, Seth G N Grant.   

Abstract

We isolated the postsynaptic density from human neocortex (hPSD) and identified 1,461 proteins. hPSD mutations cause 133 neurological and psychiatric diseases and were enriched in cognitive, affective and motor phenotypes underpinned by sets of genes. Strong protein sequence conservation in mammalian lineages, particularly in hub proteins, indicates conserved function and organization in primate and rodent models. The hPSD is an important structure for nervous system disease and behavior.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170055      PMCID: PMC3040565          DOI: 10.1038/nn.2719

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


Synapses are fundamental structures linking nerve cells and it is essential to characterise human synapse proteins to understand the extent and relevance of synapses to human disease and behavior, and to identify new diagnostic and therapeutic approaches. From neocortical biopsies of nine adults (Supplementary Table 1), the hPSD was isolated (Supplementary Fig. 1a) and proteomic profiling using LC–MS/MS provided comprehensive protein identification: of a total of 1461 proteins (total hPSD), 748 were detected in all three replicates (consensus hPSD; Supplementary Table 2; used for all subsequent analysis, except where explicitly stated otherwise). These data provide a novel resource and are freely available in the G2Cdb database (www.genes2cognition.org/HUMAN–PSD). This proteomic data allows the first systematic analysis of the disease impact of mutations in hPSD proteins. Annotation of monogenic diseases from the Online Mendelian Inheritance in Man (OMIM) database1 was chosen for this purpose because it is primarily derived from linkage studies, which are statistically more robust and less prone to artifacts than targeted association studies. These annotations revealed 269 diseases that result from mutations in 199 hPSD genes (14% of all hPSD genes). 133 of these diseases (~50%) are primary nervous system disorders (Supplementary Tables 3 and 4). Of these, ~80% were central and ~20% were peripheral nervous system disorders. Similar proportions were seen in the consensus hPSD: 155 diseases arose from mutations in 110 genes and 82 were nervous system diseases. Although the number of brain diseases involved in the hPSD is striking, overall these arise from only 14% of hPSD genes, therefore we expect many more mutations and diseases to be discovered by future human disease genome projects. To classify these diseases the International Classification of Disease (ICD–10) was used, and from 22 ICD–10 chapters, four represented hPSD diseases: neurology (chapter VI), psychiatry (V), developmental (XVII) and metabolic (IV) diseases (Fig. 1a). These included common neurodegenerative diseases (Alzheimer’s, Parkinson’s, Huntington’s), adult and childhood cognitive disorders such as mental retardation, motor disorders such as ataxia or dystonia, epilepsies and many rare diseases.
Fig. 1

hPSD Diseases and Enriched Phenotypes

a. Distribution of hPSD nervous system diseases in 4 ICD–10 chapters (left chart) with Chapter VI expanded (right chart) to show further subclassifications.

b. Representative human and mouse phenotypes enriched in the hPSD.

Categories (bold) of human and mouse phenotypes with number of genes (hPSD genes). Heatmap compares enrichment of these phenotypes in 4 gene sets relative to the enrichment of the hPSD (shown in red). All other gene sets showed lower enrichment (darker colors with black representing no enrichment). Neuron. human cortical neuron transcriptome9; brain, whole mouse brain proteome; astrocyte, human astrocyte transcriptome10; and human genome.

Hs, human; Mm, mouse.

HPO and MPO phenotype IDs in brackets after each named phenotype.

Each disease class is defined by similar clinical phenotypes and these are systematically categorised in the Human Phenotype Ontology (HPO)2. Because HPO phenotypes are linked to gene mutations (via OMIM) we could use gene set enrichment analysis (see ) to identify the phenotypes most relevant for the hPSD compared to non–PSD brain expressed proteins. As shown in Figure 1b and Supplementary Table 5, we found the hPSD was significantly enriched in 21 neural phenotypes primarily involving cognition and motor functions. Some were represented by large sets of genes, such as mental retardation (40 genes) and spasticity (20 genes), indicating subsets of the hPSD proteome play key roles in these functions. The enrichment observed in general disease phenotypes (Fig. 1b) such as neurological abnormality indicates the hPSD is a neuronal structure with a disproportionately high density of neural disease susceptibility. A powerful way to extend this analysis of hPSD function is to examine the role of hPSD gene orthologs in mice, an important animal model of human disease. Moreover, there is a wider range of behavioural, physiological and anatomical phenotypes that can be investigated for enrichment in the hPSD. From a database analogous to HPO (Mammalian Phenotype Ontology, MPO)3, the hPSD was enriched in 77 neural phenotypes (compared to other sets of brain proteins, Supplementary Table 6), which included cognitive and motor phenotypes, consistent with the enrichments found in the HPO analysis (Fig. 1b and Supplementary Table 7). The MPO also bridges to cellular level data, where we found neuronal morphology (83 genes), neurodegeneration (23 genes), synaptic transmission (38 genes) and plasticity (41 genes) were hPSD enriched phenotypes. The sets of genes underpinning these enriched phenotypes include components of known signalling mechanisms; for example in the learning/memory/conditioning gene set (57 genes), the N–methyl–D–aspartate (NMDA) receptor and PSD–95 interacting proteins were present, along with other proteins that are potentially involved with the same signalling process. We next examined the conservation of hPSD protein coding sequences between humans, other primates (chimpanzee, Pan troglodytes and macaque, Macaca mulatta) and rodents (mouse, Mus musculus and rat, Rattus norvegicus) (Supplementary Table 8) using the dN/dS ratio; dN measures the rate of amino acid substitution and dS reflects the background rate of neutral DNA change4. When comparing human and mouse, which evolved from lineages that diverged from a last common ancestor (LCA) ~90my ago, the median dN/dS for hPSD genes was very significantly (p < 10−148) less than the whole genome (protein coding genes only) (Supplementary Fig. 2b). A similar highly significant conservation in hPSD proteins was found in other pairs of compared species: human/chimp (LCA~6 my), human/macaque (LCA~30 my) and mouse/rat (LCA ~20 my)5 showing the purifying selection (conservation) was not unique to the human lineage (Supplementary Fig. 2c–e). Since it has been reported that general brain proteins evolved slower than proteins in other tissues6-8, we asked if hPSD conservation was a reflection of broader conservation observed in brain proteins. Unexpectedly, the hPSD was significantly more conserved than all three non–PSD brain expressed gene sets9-11 (Fig. 2a, Supplementary Fig. 3 and Table 9). The extent of the hPSD conservation was further revealed by comparison with 7 other neuronal subcellular structures (including mitochondria, endoplasmic reticulum and nucleus), which were all less conserved (Fig. 2b, Supplementary Table 10). Since postsynaptic complexes are rich in protein interactions12, and a slower rate of evolution has been reported for proteins with many interactions13, we constructed an hPSD interaction network (Supplementary Fig. 4). Highly interconnected (hub) proteins and proteins in the multiprotein complexes bound to PSD–9514 showed significantly lower dN/dS than other hPSD proteins (Fig. 2c, Supplementary Table 11). These data indicate that hPSD structural organisation plays a role in the conservation of hPSD protein sequence.
Fig. 2

hPSD sequence conservation

a. Cumulative frequency plot of dN/dS values for hPSD and non–PSD genes expressed in cortical neurons9, and human genome. hPSD neuronal genes are more constrained than non–PSD neuronal genes (p < 10−11).

b. Median mouse–human dN/dS shown for hPSD and subcellular structures expressed in cortical neurons9. Significance: p < 0.05 (*), p< 0.001 (***).

c, Boxplots of dN/dS distribution in hPSD hub proteins (>15 interactions, n = 23), non–hubs (≤15 interactions, n = 725) and the tandem affinity purification of PSD–95 complex14.

This study reveals the human PSD has a high degree of molecular complexity with over 1000 proteins and deepens our understanding of synaptic disease biology by showing that combinations of proteins regulate the phenotypes of over 130 brain diseases. It is possible, and indeed likely, that the proteins identified represent an overall synaptic parts list, with subsets of synapses containing subsets of these proteins. Further sensitive and high–resolution proteomic work will be necessary to expand our knowledge of regional and microscopic synapse heterogeneity. Our data provides a valuable resource and template for investigating human synapse function and suggests new diagnostic and therapeutic approaches.
  14 in total

1.  Elevated rates of protein secretion, evolution, and disease among tissue-specific genes.

Authors:  Eitan E Winter; Leo Goodstadt; Chris P Ponting
Journal:  Genome Res       Date:  2004-01       Impact factor: 9.043

Review 2.  The Ka/Ks ratio: diagnosing the form of sequence evolution.

Authors:  Laurence D Hurst
Journal:  Trends Genet       Date:  2002-09       Impact factor: 11.639

3.  TimeTree: a public knowledge-base of divergence times among organisms.

Authors:  S Blair Hedges; Joel Dudley; Sudhir Kumar
Journal:  Bioinformatics       Date:  2006-10-04       Impact factor: 6.937

4.  Characterization of the mouse brain proteome using global proteomic analysis complemented with cysteinyl-peptide enrichment.

Authors:  Haixing Wang; Wei-Jun Qian; Mark H Chin; Vladislav A Petyuk; Richard C Barry; Tao Liu; Marina A Gritsenko; Heather M Mottaz; Ronald J Moore; David G Camp Ii; Arshad H Khan; Desmond J Smith; Richard D Smith
Journal:  J Proteome Res       Date:  2006-02       Impact factor: 4.466

5.  The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease.

Authors:  Peter N Robinson; Sebastian Köhler; Sebastian Bauer; Dominik Seelow; Denise Horn; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2008-10-23       Impact factor: 11.025

6.  Mendelian Inheritance in Man and its online version, OMIM.

Authors:  Victor A McKusick
Journal:  Am J Hum Genet       Date:  2007-03-08       Impact factor: 11.025

7.  The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour.

Authors:  Andrew J Pocklington; Mark Cumiskey; J Douglas Armstrong; Seth G N Grant
Journal:  Mol Syst Biol       Date:  2006-01-17       Impact factor: 11.429

8.  The Mammalian Phenotype Ontology as a tool for annotating, analyzing and comparing phenotypic information.

Authors:  Cynthia L Smith; Carroll-Ann W Goldsmith; Janan T Eppig
Journal:  Genome Biol       Date:  2004-12-15       Impact factor: 13.583

9.  A simple dependence between protein evolution rate and the number of protein-protein interactions.

Authors:  Hunter B Fraser; Dennis P Wall; Aaron E Hirsh
Journal:  BMC Evol Biol       Date:  2003-05-23       Impact factor: 3.260

10.  The cerebral microvasculature in schizophrenia: a laser capture microdissection study.

Authors:  Laura W Harris; Matthew Wayland; Martin Lan; Margaret Ryan; Thomas Giger; Helen Lockstone; Irene Wuethrich; Michael Mimmack; Lan Wang; Mark Kotter; Rachel Craddock; Sabine Bahn
Journal:  PLoS One       Date:  2008-12-17       Impact factor: 3.240

View more
  227 in total

Review 1.  NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders.

Authors:  Charles F Zorumski; Yukitoshi Izumi
Journal:  Neurosci Biobehav Rev       Date:  2012-01-02       Impact factor: 8.989

Review 2.  Glial Contributions to Neural Function and Disease.

Authors:  Matthew N Rasband
Journal:  Mol Cell Proteomics       Date:  2015-09-04       Impact factor: 5.911

Review 3.  Proteomics of the Synapse--A Quantitative Approach to Neuronal Plasticity.

Authors:  Daniela C Dieterich; Michael R Kreutz
Journal:  Mol Cell Proteomics       Date:  2015-08-25       Impact factor: 5.911

4.  Neuroproteomics: How Many Angels can be Identified in an Extract from the Head of a Pin?

Authors:  Jeffery L Twiss; Mike Fainzilber
Journal:  Mol Cell Proteomics       Date:  2016-01-04       Impact factor: 5.911

5.  Laser capture microdissection-targeted mass spectrometry: a method for multiplexed protein quantification within individual layers of the cerebral cortex.

Authors:  Matthew L MacDonald; Daley Favo; Megan Garver; Zhe Sun; Dominique Arion; Ying Ding; Nathan Yates; Robert A Sweet; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2018-11-02       Impact factor: 7.853

6.  Synaptosomal lactate dehydrogenase isoenzyme composition is shifted toward aerobic forms in primate brain evolution.

Authors:  Tetyana Duka; Sarah M Anderson; Zachary Collins; Mary Ann Raghanti; John J Ely; Patrick R Hof; Derek E Wildman; Morris Goodman; Lawrence I Grossman; Chet C Sherwood
Journal:  Brain Behav Evol       Date:  2014-03-28       Impact factor: 1.808

Review 7.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

8.  Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Authors:  Alberto Lleó; Raúl Núñez-Llaves; Daniel Alcolea; Cristina Chiva; Daniel Balateu-Paños; Martí Colom-Cadena; Gemma Gomez-Giro; Laia Muñoz; Marta Querol-Vilaseca; Jordi Pegueroles; Lorena Rami; Albert Lladó; José L Molinuevo; Mikel Tainta; Jordi Clarimón; Tara Spires-Jones; Rafael Blesa; Juan Fortea; Pablo Martínez-Lage; Raquel Sánchez-Valle; Eduard Sabidó; Àlex Bayés; Olivia Belbin
Journal:  Mol Cell Proteomics       Date:  2019-01-03       Impact factor: 5.911

9.  Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes.

Authors: 
Journal:  Cell       Date:  2018-06-14       Impact factor: 41.582

10.  Cerebrospinal fluid proteome of patients with acute Lyme disease.

Authors:  Thomas E Angel; Jon M Jacobs; Robert P Smith; Mark S Pasternack; Susan Elias; Marina A Gritsenko; Anil Shukla; Edward C Gilmore; Carol McCarthy; David G Camp; Richard D Smith; H Shaw Warren
Journal:  J Proteome Res       Date:  2012-08-31       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.